Cargando…
Biosimilar agents in oncology/haematology: from approval to practice
The regulation of biosimilars is a process that is still developing. In Europe, guidance regarding the approval and use of biosimilars has evolved with the products under consideration. It is now more than 3 years since the first biosimilar agents in oncology support, erythropoiesis-stimulating agen...
Autores principales: | Niederwieser, Dietger, Schmitz, Stephan |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3085072/ https://www.ncbi.nlm.nih.gov/pubmed/21175852 http://dx.doi.org/10.1111/j.1600-0609.2010.01566.x |
Ejemplares similares
-
On the Regulatory Approval Pathway of Biosimilar Products
por: Wang, Jun, et al.
Publicado: (2012) -
Current and future roles of biosimilars in oncology practice
por: Konstantinidou, Sofia, et al.
Publicado: (2020) -
Integrating Biosimilars Into Oncology Practice: Implications for the Advanced Practitioner
por: Campen, Christopher J.
Publicado: (2017) -
An Overview of Current Regulatory Requirements for Approval of Biosimilar Insulins
por: Heinemann, Lutz, et al.
Publicado: (2015) -
Pharmacodynamic Biomarkers Evidentiary Considerations for Biosimilar Development and Approval
por: Strauss, David G., et al.
Publicado: (2022)